Susceptibility Testing of Colistin for Acinetobacter baumannii: How Far Are We from the Truth?

Acinetobacter baumannii is involved in life-threatening nosocomial infections, mainly in the intensive care units (ICUs), and often colistin may represent the last therapeutic opportunity. The susceptibility to colistin of 51 epidemiologically typed A. baumannii strains isolated in 2017 from clinical samples of patients hospitalized in the ICU of a tertiary care academic hospital was investigated. All isolates were carbapenem-resistant due to the presence of the bla(OXA-23) gene in sequence group 1 (international clonal lineage II) and sequence group 4 (related to international clonal lineage II) isolates, and to the bla(OXA-24/40) gene in sequence group 2 (international clonal lineage I) isolates. Vitek (R)2, agar diffusion, and broth microdilution tests showed major discordancy (>= 2 dilution factors) in the minimum inhibitory concentration (MIC) values for colistin in 24 out of 51 isolates, resulting in erroneous reporting of qualitative susceptibility data for eight isolates. In growth kinetics experiments in the presence of colistin, five isolates grew with drug concentrations above the susceptibility breakpoint when incubated for >12 h, and three isolates showed the presence of heteroresistant subpopulations. This study highlights that the high frequency of isolation of carbapenem-resistant A. baumannii strains in high-risk infectious wards requires an accurate application of methods for detecting susceptibility to antibiotics, in particular to colistin, so as to ensure a correct therapeutic approach.

Automated summary

This study found that Acinetobacter baumannii isolates in ICU patients often show resistance to the last therapeutic option, colistin, due to variations in resistance mechanisms. The high frequency of isolation of carbapenem-resistant A. baumannii strains emphasizes the need for accurate methods to detect antibiotic susceptibility, particularly to colistin, to ensure proper therapeutic approaches.